Stock Yearly Return 2021
Start date: 01/04/2021
End date: 12/31/2021
Start price/share: $17.95
End price/share: $2.96
Dividends collected/share: $0.00
Total return: -83.51%
YMTX Average Annual Return: -84.44%
Starting investment: $10,000.00
Ending investment: $1,649.00
Years: 0.99


YMTX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare YMTX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into YMTX


Also see:
YMTX YTD return
YMTX average annual return 10 years
Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in Phase 1 clinical trials for the treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase, or SCD. Co. has completed a Phase 1 study of YTX-7739 in healthy volunteers, which evaluated a range of doses of YTX-7739. Co.'s second program, YTX-9184, also inhibits SCD. Co. is developing YTX-9184 for the treatment of dementia with Lewy bodies, which is a neurodegenerative disease characterized by the abnormal accumulation of aggregates of a-synuclein. The YMTX stock yearly return is shown above.

The yearly return on the YMTX stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2021 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the YMTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree YMTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Yumanity Therapeutics (YMTX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

YTEN Average Annual Return
ZBH Average Annual Return
ZGNX Average Annual Return
ZIOP Average Annual Return
ZNTL Average Annual Return
ZSAN Average Annual Return
ZTS Average Annual Return
ZY Average Annual Return
ZYNE Average Annual Return
ZYXI Average Annual Return
More Healthcare companies »

 

YMTX Stock Yearly Return 2021 | www.AverageAnnualReturn.com | Copyright © 2021 - 2022, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.